Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Post Results Conference Call With Investors / Analysts

 We inform that the Company will declare its Financial Results for Q4 2016-17 (January-March 2017) on May 27, 2017. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company will hold post results Q & A session through teleconference with investors/analysts on May 27, 2017 at 6.00 p.m. to discuss the financial performance of the Company for the quarter ended on March...
18-05-2017
Bigul

Press Release

 Zydus wins Federal Circuit Appeal in generic version of Lialda (Mesalamine).
10-05-2017
Bigul

Zydus Cadila gets final USFDA nod for Budesonide Capsules

 Cadila Healthcare (Zydus Cadila) on Friday informed that the company has received final approval from the US regulator, US Food and Drug Administration (USFDA) to market Budesonide Capsules in 3 mg...
05-05-2017
Bigul

Press Release

 Zydus receives final approval from the USFDA for Budesonide Capsules.
05-05-2017
Bigul

Intimation Of Meeting Of Board Of Directors Scheduled To Be Held On May 27, 2017 And Closure Of Trading Windows.

 In compliance with the provisions of Regulation 29 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation 2015, we hereby inform that the meeting of the Board of Directors of the Company will be held on Saturday, the May 27, 2017 to consider, inter alia, to approve the Audited Financial Results for the year ended on March 31, 2017. We further inform that as per Code of Conduct for prevention of Insider Trading adopted by the...
29-04-2017
Bigul

Zydus Cadila gets USFDA nod for anti-hypertensive tablets

 Healthcare player Zydus Cadila informed about receiving the final approval from the US drug regulator US Food and Drug Administration (USFDA) to market Olmesartan Medoxomil tablets in the US market.
26-04-2017
Bigul

Updates

 We enclose herewith a copy of press release dated April 26, 2017, titled Zydus receives final approval from the USFDA for Cholestyramine for Oral Suspension USP.
26-04-2017
Bigul

Zydus Cadila gets final USFDA nod for Olmesartan Medoxomil tablets

 Healthcare player Zydus Cadila on Tuesday informed about receiving the final approval from the US Food and Drug Administration (USFDA) to market Olmesartan Medoxomil tablets in the US market. The...
25-04-2017
Bigul

Updates

 Zydus receives final approval from the USFDA for Olmesartan Medoxomil Tablets. The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.
25-04-2017
Bigul

Certificate Under Regulation 40 (9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended On March 31, 2017.

 In compliance with the provisions of Regulation 40 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are forwarding herewith the Certificate of Mr. Manoj Hurkat, Practicing Company Secretary for the Half Year ended on March 31, 2017 received on April 13, 2017
13-04-2017
Next Page
Close

Let's Open Free Demat Account